Sanoculis Secures CE Mark for MINT® Glaucoma Treatment Technology

Sanoculis Achieves CE Mark Approval for MINT® Glaucoma Treatment



Sanoculis Ltd., a pioneering company specializing in ophthalmic medical device technology, has recently announced an important milestone in the treatment of glaucoma. The company has received the CE mark for its innovative product named MINT® (Minimally Invasive Nasal Trabeculostomy). This approval aligns with the European Union's Medical Device Regulation (MDR) and indicates that MINT® meets the necessary safety and efficacy standards for medical devices marketed in Europe.

MINT® employs a unique semi-automated mechanical trepanation technology, utilizing a state-of-the-art diameter of just 0.14 mm. This groundbreaking technique enables the creation of precise openings in the trabecular meshwork, which is a critical component in the drainage system of the eye. This stent-free approach is set to redefine treatment standards by offering a less invasive, yet more effective, option for adult patients undergoing surgery for glaucomatous conditions.

According to Nir Israeli, co-founder and CEO of Sanoculis, "MINT® represents a significant transformation in the realm of minimally invasive glaucoma surgery (MIGS). With robust clinical data from our prospective single-arm study boasting a two-year follow-up, we can confirm that MINT® is safe and effective in lowering intraocular pressure while also decreasing the need for glaucoma medications."

The statistics surrounding glaucoma highlight the urgent need for advanced treatments. Currently, glaucoma affects approximately 76 million individuals globally, with projections suggesting this figure could rise to 112 million by 2040. Glaucoma ranks as the second leading cause of irreversible blindness worldwide. Most forms of the disease are chronic, and if left undetected or untreated, they can lead to irreversible vision loss. Early detection and timely intervention are essential to protect against vision deterioration, which occurs when the optic nerve is damaged, resulting in progressive visual field loss. The only established treatment for glaucoma involves reducing intraocular pressure (IOP) and slowing visual field progression.

Treatment protocols typically start with topical eye drops and can escalate to laser therapy or minimally invasive solutions like MIGS before resorting to conventional, more invasive filtering surgeries. MINT® aims to provide a less invasive treatment option right from the onset of glaucoma intervention strategies.

With clinical studies backing its effectiveness, Sanoculis plans to initiate a selective commercial launch of MINT® later this year, paving the way for improved patient outcomes in glaucoma surgery.

About Sanoculis


Sanoculis Ltd. is committed to advancing ophthalmic medical technology, focusing on minimally invasive and stent-free solutions for performing sclerostomies and trabeculostomies during glaucoma angle surgeries. The company’s mission is to enhance the quality of healthcare and clinical outcomes for glaucoma patients through innovative technological platforms.

For More Information


For inquiries or to learn more about MINT® and its availability, reach out to Elad Shalev, Global VP of Marketing and Sales, at [email protected] or via phone at +972509827282.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.